Quality of life in patients diagnosed of prostate cancer treated with continuous androgen deprivation therapy vs. intermittent therapy. Prospective study through the application of the CAVIPRES questionnaire
DOI:
https://doi.org/10.23938/ASSN.0068Keywords:
Quality of life. Prostate cancer. Intermittent androgen deprivation.Abstract
Background. Treatment with intermittent androgen deprivation (IAD) seeks to improve the quality of life of patients with prostate cancer, with the same oncologic results as continuous androgen deprivation (CAD). The aim of this paper is to compare, using the CAVIPRES questionnaire, the quality of life between two groups of patients, one treated with CAD and the other with IAD.
Materials and methods. A longitudinal study was performed for 24 months involving 114 patients. After 6 months, patients were randomized to two treatment groups (49 patients in CAD and 51 patients in IAD), controlled at 6, 12 and 18 months from randomisation. The score of the items and the overall score of the CAVIPRES questionnaire between the two groups was compared and their variation over time was studied.
Results. Patients with IAD had a better overall score than patients with CAD (p=0.002). Of the 5 blocks of items into which the questionnaire was divided, the IAD group had a better score than CAD in “Psychological aspects” (p=0.009) and “Social and partner support” (p=0.008). At 18 months, IAD improved the overall quality of life of patients relative to the time of randomization (p=0.000), as well as the score for "Sexual Life" (p=0.000) and "Social and partner support" (p=0.002). CAD did not improve overall quality of life or the score for the different blocks throughout the study (p>0.05).
Conclusions. IAD improves overall quality of life of patients at 18 months of stopping treatment.
Downloads
References
1. Constitution of the World Health Organization. Am J Public Health Nations Health 1946; 36: 1315-1323.
https://doi.org/10.2105/AJPH.36.11.1315
2. MINAYO MC, HARTZ ZM, BUSS P. Quality of life and Health: a necessary debate. Ciencia & Saúde Coletiva ABRASCO 2000; 1: 7-18.
https://doi.org/10.1590/S1413-81232000000100002
3. PTACEK JT, FRIES EA, EBERHARDT TL, PTACEK JJ. Breaking bad news to patients: physicians' perceptions of the process. Support Care Cancer 1999; 7: 113-120.
https://doi.org/10.1007/s005200050240
4. BARCELÓ OBRADOR A, RAMOS M, DE LA IGLESIA M, ZAFORTEZA M. Tratamiento del cáncer de próstata en función de la esperanza de vida, la comorbilidad y las guías de práctica clínica. An Sis Sanit Navar 2014; 37: 339-348.
https://doi.org/10.4321/S1137-66272014000300004
5. OLIVER RT, WILLIAMS G, PARIS AM, BLANDY JP. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology 1997; 49: 79-82.
https://doi.org/10.1016/S0090-4295(96)00373-1
6. BHANDARI MS, CROOK J, HUSSAIN M. Should intermittent androgen deprivation be used in routine clinical practice? J Clin Oncol 2005; 23: 8212-8218.
https://doi.org/10.1200/JCO.2005.03.2557
7. LÓPEZ JD, LÓPEZ-FONTANA G, LÓPEZ-FONTANA R. Evidencia actual acerca de bloqueo hormonal intermitente en cáncer de próstata. Actas Urol Esp 2012; 36: 608-612.
https://doi.org/10.1016/j.acuro.2012.02.007
8. SCHWARTZMANN L. Calidad de vida relacionada con la salud: aspectos conceptuales. Cienc enferm [online]. 2003; 9: 9-21.
https://doi.org/10.4067/S0717-95532003000200002
9. GÓMEZ-VEIGA F, COZAR-OLMO JM, GÜNTHNER S, PUYOL-PALLAS M, SILMI-MOYANO A, BARÓ-RAMOS E et al. Desarrollo y validación del primer cuestionario español de calidad de vida en pacientes con cáncer de próstata, basado en la percepción del paciente. Actas Urol Esp 2009; 33: 623-634.
https://doi.org/10.1016/S0210-4806(09)74200-7
10. GÓMEZ-VEIGA F, SILMI-MOYANO A, GÜNTHNER S, PUYOL-PALLAS M, COZAR-OLMO JM. Valores de referencia para el cuestionario CAVIPRES-30, un cuestionario global sobre la calidad de vida relacionada con la salud de pacientes con cáncer de próstata. Actas Urol Esp 2014; 38: 304-312.
https://doi.org/10.1016/j.acuro.2013.09.003
11. GOMELLA LG, JOHANNES J, TRABULSI EJ. Current prostate cancer treatments: effect on quality of life. Urology 2009; 73 (5 Suppl): S28-35.
https://doi.org/10.1016/j.urology.2009.03.003
12. HUSSON O, MOLS F, VAN DE POLL-FRANSE LV. The relation between information provision and health-related quality of life, anxiety and depression among cancer survivors: A systematic review. Ann Oncol 2011; 22: 761-772.
https://doi.org/10.1093/annonc/mdq413
13. ESPER P, MO F, CHODAK G, SINNER M, CELLA D, PIENTA KJ. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology 1997; 50: 920-928.
https://doi.org/10.1016/S0090-4295(97)00459-7
14. VAN ANDEL G, BOTTOMLEY A, FOSSA SD, EFFICACE F, COENS C, GUERIF S et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer 2008; 44: 2418-2424.
https://doi.org/10.1016/j.ejca.2008.07.030
15. LITWIN MS. Measuring health related quality of life in men with prostate cancer. J Urol 1994; 152 (5 Pt 2): 1882-1887.
https://doi.org/10.1016/S0022-5347(17)32407-2
16. HAYS RD, SHERBOURNE CD, MAZEL RM. The RAND 36-Item Health Survey 1.0. Health Econ 1993; 2: 217-227.
https://doi.org/10.1002/hec.4730020305
17. WEI JT, DUNN RL, LITWIN MS, SANDLER HM, SANDA MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000; 56: 899-905.
https://doi.org/10.1016/S0090-4295(00)00858-X
18. TANNOCK IF, OSOBA D, STOCKLER MR, ERNST DS, NEVILLE AJ, MOORE MJ et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
https://doi.org/10.1200/JCO.1996.14.6.1756
19. OSOBA D, TANNOCK IF, ERNST DS, NEVILLE AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 1654-1663.
https://doi.org/10.1200/JCO.1999.17.6.1654
20. FERRER M, GARÍN O, PERA J, PRATS JM, MENDIVIL J, ALONSO J et al. Evaluación de la calidad de vida de los pacientes con cáncer de próstata localizado: validación de la versión española del cuestionario EPIC. Med Clin (Barc) 2009; 132: 128-135.
https://doi.org/10.1016/j.medcli.2008.01.001
21. PARKER WR, MONTGOMERY JS, WOOD DP, JR. Quality of life outcomes following treatment for localized prostate cancer: is there a clear winner? Curr Opin Urol 2009; 19: 303-308.
https://doi.org/10.1097/MOU.0b013e328329eb00
22. COCKS K, KING MT, VELIKOVA G, FAYERS PM, BROWN JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer 2008; 44: 1793-1798.
https://doi.org/10.1016/j.ejca.2008.05.008
23. GÓMEZ-VEIGA F, COZAR JM, GÜNTHNER S, PUYOL-PALLAS M, SILMI-MOYANO A, REBOLLO FJ. Cuestionario Español de Calidad de Vida en Pacientes con Cáncer de Próstata como medida de la calidad de vida de los pacientes con cáncer de próstata en España: aplicación a la actividad diaria. Actas Urol Esp 2010; 34: 686-693.
https://doi.org/10.1016/j.acuro.2010.05.001
24. HUSSAIN M, TANGEN CM, HIGANO C, SCHELHAMMER PF, FAULKNER J, CRAWFORD ED et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006; 24: 3984-3990.
https://doi.org/10.1200/JCO.2006.06.4246
25. MOUL JW, WU H, SUN L, MCLEOD DG, AMLING C, DONAHUE T et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2008; 179 (5 Suppl): S53-59.
https://doi.org/10.1016/j.juro.2008.03.138
26. PRAPOTNICH D, SANCHEZ-SALAS R, CATHELINEAU X, STAKHOVSKYI O, ROCHA JE, JR, VALLANCIEN G. Bloqueo androgénico intermitente (BAI) en cáncer de próstata avanzado. ¿Por qué no el tratamiento estándar? Arch Esp Urol 2009; 62: 689-694.
https://doi.org/10.4321/S0004-06142009000900001
27. CALAIS DA SILVA FE, BONO AV, WHELAN P, BRAUSI M, MARQUES QUEIMADELOS A, MARTIN JA et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol 2009; 55: 1269-1277.
https://doi.org/10.1016/j.eururo.2009.02.016
28. SPRY NA, KRISTJANSON L, HOOTON B, HAYDEN L, NEERHUT G, GURNEY H et al. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006; 42: 1083-1092.
https://doi.org/10.1016/j.ejca.2006.01.029
29. ABRAHAMSSON PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur Urol 2010; 57: 49-59.
https://doi.org/10.1016/j.eururo.2009.07.049
30. BUCHAN NC, GOLDENBERG SL. Intermittent versus continuous androgen suppression therapy: do we have consensus yet? Curr Oncol 2010; 17 Suppl 2: S45-48.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2015 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
